ロード中...
MR Imaging Biomarkers to Monitor Early Response to Hypoxia-Activated Prodrug TH-302 in Pancreatic Cancer Xenografts
TH-302 is a hypoxia-activated prodrug known to activate selectively under the hypoxic conditions commonly found in solid tumors. It is currently being evaluated in clinical trials, including two trials in Pancreatic Ductal Adenocarcinomas (PDAC). The current study was undertaken to evaluate imaging...
保存先:
| 出版年: | PLoS One |
|---|---|
| 主要な著者: | , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Public Library of Science
2016
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4882075/ https://ncbi.nlm.nih.gov/pubmed/27227903 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0155289 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|